Overview
Professor Needham has been at Duke since 1987 and over the years has developed many collaborative and scholarly relationships across the campus and Medical School. He holds Faculty and membership appointments as: Associate Professor of Biomedical Engineering; Center for Bioinspired Materials and Material Systems; Center for Biomolecular and Tissue Engineering; Duke Comprehensive Cancer Center; and the Duke Cancer Institute. Internationally, he holds a joint appointment as Professor of Translational Therapeutics in the School of Pharmacy, at the University of Nottingham, UK. He also collaborates with preclinical researchers at the Erasmus University Medical Center, in Rotterdam, NL.
For the past 35 years Needham's Lab has developed and used a platform technology of micropipette manipulation to manipulate single and pairs of micro bubbles, droplets and particles in order to assess their behavior in well-defined fluids and solution conditions. Recently his research and development has focused on nucleation, growth and stability of nanoparticles. Applications of these fundamental particle and interfacial studies have primarily focused on advanced drug delivery treatments for cancer and now COVID19 with a nasal and throat spray prophylactic and early treatment regimen.
Current Appointments & Affiliations
Recent Publications
Novel niclosamide stearate prodrug therapeutic shows potential efficacy against naturally occurring canine osteosarcoma in a clinical feasibility study.
Journal Article Am J Vet Res · January 1, 2026 OBJECTIVE: To manufacture and characterize a modified niclosamide stearate (NS) prodrug therapeutic (mNSPT) for use in a small clinical trial in a metastatic canine osteosarcoma (OS) model. ANIMALS: 10 dogs that presented for treatment of nondetectable met ... Full text Link to item CiteLDLR-targeted orlistat therapeutic nanoparticles: Peptide selection, assembly, characterization, and cell-uptake in breast cancer cell lines.
Journal Article International journal of pharmaceutics · May 2025 MotivationMany cancers overexpress low-density lipoprotein receptors (LDLR), facilitating cholesterol metabolism for tumour growth. Targeting LDLR offers a promising strategy for selective drug delivery. Orlistat, a fatty acid synthase (FAS) inhib ... Full text CiteNiclosamide: A career builder.
Journal Article Journal of controlled release : official journal of the Controlled Release Society · May 2024 My contribution to honoring Professor Kinam Park celebrates and resonates with his scholarly career in drug delivery, his commitment to encouraging the next generation(s), and his efforts to keep us focused on clinically effective formulations. To do this ... Full text CiteRecent Grants
Niclosamide spray as a prophylactic and early treatment for SARS-CoV-2
ResearchCo Investigator · Awarded by American Lung Association · 2021 - 2023TRP and AQP Channels: Modulation of Function, Raft Location by Membrane Lipids
ResearchConsultant · Awarded by National Institutes of Health · 1980 - 2015PLGA Protein Microspheres: Single Particle Engineering
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2006 - 2011View All Grants